Yueshan Piao

Yueshan Piao

Auto-generated profile, based on publicly available information

Yueshan Piao

Department of Pathology, Xuanwu Hospital, Capital Medical University, Beijing, China

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2022 in Epilepsia
Verified
Journal Article
Open access
INImad Najm
Imad Najm
DLDennis Lal
Dennis Lal
MVMARIO ALONSO VANEGAS
MARIO ALONSO VANEGAS
FCFernando Cendes
Fernando Cendes
Iscia Lopes-CendesIscia Lopes-Cendes
Iscia Lopes-Cendes
IBIngmar Blumcke
Ingmar Blumcke
Ongoing challenges in diagnosing focal cortical dysplasia (FCD) mandate continuous research and consensus agreement to improve disease definition and classification. An International League Against Epilepsy (ILAE) Task Force (TF) reviewed the FCD classification of 2011 to identify existing gaps and provide a timely update. The following methodology was applied to achieve this goal: a survey of published literature indexed with ((Focal Cortical Dysplasia) AND (epilepsy)) between 01/01/2012 and 06/30/2021 (n = 1349) in PubMed identified the knowledge gained since 2012 and new developments in the field. An online survey consulted the ILAE community about the current use of the FCD classification scheme with 367 people answering. The TF performed an iterative clinico‐pathological and genetic agreement study to objectively measure the diagnostic gap in blood/brain samples from 22 patients suspicious for FCD and submitted to epilepsy surgery. The literature confirmed new molecular‐genetic characterizations involving the mechanistic Target Of Rapamycin (mTOR) pathway in FCD type II (FCDII), and SLC35A2 in mild malformations of cortical development (mMCDs) with oligodendroglial hyperplasia (MOGHE). The electro‐clinical‐imaging phenotypes and surgical outcomes were better defined and validated for FCDII. Little new information was acquired on clinical, histopathological, or genetic characteristics of FCD type I (FCDI) and FCD type III (FCDIII). The survey identified mMCDs, FCDI, and genetic characterization as fields for improvement in an updated classification. Our iterative clinico‐pathological and genetic agreement study confirmed the importance of immunohistochemical staining, neuroimaging, and genetic tests to improve the diagnostic yield. The TF proposes to include mMCDs, MOGHE, and “no definite FCD on histopathology” as new categories in the updated FCD classification. The histopathological classification can be further augmented by advanced neuroimaging and genetic studies to comprehensively diagnose FCD subtypes; these different levels should then be integrated into a multi‐layered diagnostic scheme. This update may help to foster multidisciplinary efforts toward a better understanding of FCD and the development of novel targeted treatment options.

24 February 2005 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
AIAtsushi Ishikawa
Atsushi Ishikawa
YPYue‐Shan Piao
Yue‐Shan Piao
AMAkinori Miyashita
Akinori Miyashita
RKRyozo Kuwano
Ryozo Kuwano
OOOsamu Onodera
Osamu Onodera
HTHitoshi Takahashi
Hitoshi Takahashi

8 August 2020 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
XJXin-Yue Jiang
Xin-Yue Jiang
SLSong Lei
Song Lei
LZLe Zhang
Le Zhang
XLXu Liu
Xu Liu
MLMin-Tao Lin
Min-Tao Lin
JLJinmei Li
Jinmei Li
Objective: To comprehensively describe the pathological features of neurons in patients with ovarian teratomas and paraneoplastic anti-NMDAR encephalitis (anti-NMDARE), emphasizing on NMDA-receptor expression and infiltrating lymphocytes. Methods: A retrospective study was performed in a large series of 159 patients from the West China Hospital. We retrospectively identified 12 patients with paraneoplastic anti-NMDARE (11 case with ovarian teratomas and 1 case with mixed germ cell tumor), which were compared to 35 patients with teratomas and no encephalitis and to 147 patients with anti-NMDARE and no evidence for tumors. Patient history and outcome were reviewed from the clinical charts and compared between all three groups. Histopathological examination, including double-immunofluorescence of NMDAR subunits and IgG was performed in all teratoma tissues. Magnetic Luminex Assay Human Premixed Multi-Analyte Kit was performed to investigate cytokines profile of CSF. Results: Patients with paraneoplastic anti-NMDARE had a more severe clinical presentation, i.e. they required more mechanical ventilation and intensive care (p < 0.001). Though immunotherapy was initiated earlier in this group, repeated intravenous immunoglobulin administration (IVIG) was more common (p = 0.002) and with higher cerebrospinal fluid (CSF) antibody titres (p = 0.004). Following tumor resection, the outcome did not differ between groups. A peculiar population of floating-frog like dysplastic neurons were observed only in teratomas of patients with paraneoplastic anti-NMDARE, co-expressing NR1, NR2A, NR2B subunits and IgG. Also, CD20 positive B-cells were more common in anti-NMDARE teratomas. In CSF of paraneoplastic anti-NMDARE patients, TNF-α, IL-10 and GM-CSF concentrations were higher than in negative symptom control and VEGF-A and IL-1a were lower than in anti-NMDARE patients (0.25 < p < 0.05). Conclusions: Patients with teratomas and paraneoplastic anti-NMDARE revealed a cellular population of dysplastic neurons co-expressing NMDAR subunits, which were the potential source of autoantigens triggering anti-NMDARE. Some inflammatory cytokines may be involved in pathogenesis of paraneoplastic anti-NMDARE.

27 May 2014 in Neuropathology and Applied Neurobiology
Verified
Journal Article
Closed access
PDF file
HNHai‐Chun Ni
Hai‐Chun Ni
SCShi‐Yun Chen
Shi‐Yun Chen
LCLi Chen
Li Chen
DLDe‐Hong Lu
De‐Hong Lu
YFYong‐Juan Fu
Yong‐Juan Fu
YPYue‐Shan Piao
Yue‐Shan Piao

30 October 2014 in Brain Pathology
Verified
Journal Article
Closed access
PDF file
DWDan‐Dan Wang
Dan‐Dan Wang
IBIngmar Blümcke
Ingmar Blümcke
RCRoland Coras
Roland Coras
WZWen‐Jing Zhou
Wen‐Jing Zhou
DLDe‐Hong Lu
De‐Hong Lu
YPYue‐Shan Piao
Yue‐Shan Piao

1 September 2021 in The Neurologist
Verified
Journal Article
Open access
QQQi Qin
Qi Qin
CWCuibai Wei
Cuibai Wei
YPYueShan Piao
YueShan Piao
FLFang Lian
Fang Lian
HWHao Wu
Hao Wu
JJJianping Jia
Jianping Jia
Introduction: Leptomeningeal amyloidosis (LA) represents a rare subtype of familial transthyretin (TTR) amyloidosis, characterized by deposition of amyloid in cranial and spinal leptomeninges. Of >120 TTR mutations identified, few have been associated with LA. Case Report: A 27-year-old male presented with a 2-year history of progressive symptoms including cognitive decline and right-sided weakness and numbness. Cerebrospinal fluid (CSF) analyses demonstrated high protein level. Gadolinium-enhanced magnetic resonance imaging (MRI) revealed extensive leptomeningeal enhancement over the surface of the brain and spinal cord. Pathologic analyses revealed a TTR mutation c.113A>G (p.D38G). Review Summary: Fifteen mutations and genotype-phenotype correlation of 72 LA patients have been summarized to provide an overview of LA associated with transthyretin mutations. The mean age of clinical onset was 44.9 years and the neurological symptoms primarily included cognitive impairment, headache, ataxia seizures and hearing, visual loss. CSF analysis showed elevated high CSF protein level and MRI revealed extensive leptomeningeal enhancement. Conclusion: Clinicians should be aware of this rare form of familial transthyretin amyloidosis as well as its typical MRI enhancement and high CSF protein. The important role of biopsy, genetic testing and the potential early diagnosis value of contrast MRI were suggested. Early recognition of these characteristics is important to provide misdiagnosis and shorten the time before correct diagnosis. These findings expand the phenotypic spectrum of TTR gene and have implications for the diagnosis, treatment, and systematic study of LA.